Update of the BIG 1-98 Trial: where do we stand? (Q43242062)

17 November 2017

title

Update of the BIG 1-98 Trial: where do we stand? (English)

1 reference

17 November 2017

Markus Joerger

1

1 reference

17 November 2017

Beat Thürlimann

series ordinal

2

1 reference

17 November 2017

publication date

1 October 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

18 Suppl 3

1 reference

17 November 2017

page(s)

S78-82

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Breast Cancer Patients on Endocrine Therapy Reveal More Symptoms when Self-Reporting than in Pivotal Trials: An Outcome Research Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970278-4

7 January 2021

10.1016/S0960-9776(09)70278-4

Identifiers

DOI

1 reference

17 November 2017

1 reference